BR112015031542A2 - métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores - Google Patents
métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadoresInfo
- Publication number
- BR112015031542A2 BR112015031542A2 BR112015031542A BR112015031542A BR112015031542A2 BR 112015031542 A2 BR112015031542 A2 BR 112015031542A2 BR 112015031542 A BR112015031542 A BR 112015031542A BR 112015031542 A BR112015031542 A BR 112015031542A BR 112015031542 A2 BR112015031542 A2 BR 112015031542A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- reaction prediction
- cancer
- treatment
- mdm2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
resumo métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores o presente pedido descreve um método de previsão da capacidade de reação de pacientes com câncer a tratamento com um antagonista de mdm2 das fórmulas i, ii e iii conforme descrito no presente, em que o mencionado método compreende a medição dos níveis de expressão de mrna de pelo menos mdm2, preferencialmente de um painel de quatro genes que compreende mdm2, xpc, bbc3 e cdkn2a, como biomarcador para previsão da reação.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842567P | 2013-07-03 | 2013-07-03 | |
| US201361912781P | 2013-12-06 | 2013-12-06 | |
| PCT/EP2014/064039 WO2015000945A1 (en) | 2013-07-03 | 2014-07-02 | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015031542A2 true BR112015031542A2 (pt) | 2017-07-25 |
Family
ID=51162759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015031542A BR112015031542A2 (pt) | 2013-07-03 | 2014-07-02 | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3017061B1 (pt) |
| JP (2) | JP6461126B2 (pt) |
| KR (1) | KR101879926B1 (pt) |
| CN (1) | CN105378112B (pt) |
| AU (1) | AU2014286237B2 (pt) |
| BR (1) | BR112015031542A2 (pt) |
| CA (1) | CA2912547A1 (pt) |
| HK (1) | HK1215453A1 (pt) |
| IL (1) | IL242692B (pt) |
| MX (1) | MX363584B (pt) |
| RU (1) | RU2016101514A (pt) |
| SG (1) | SG11201510816SA (pt) |
| WO (1) | WO2015000945A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101730708B (zh) | 2007-03-28 | 2013-09-18 | 哈佛大学校长及研究员协会 | 缝合多肽 |
| US9096684B2 (en) | 2011-10-18 | 2015-08-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP3094746A1 (en) * | 2014-01-14 | 2016-11-23 | Daiichi Sankyo Company, Limited | Gene signatures associated with sensitivity to mdm2 inhibitors |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| WO2016056673A1 (en) * | 2014-10-09 | 2016-04-14 | Daiichi Sankyo Company, Limited | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
| WO2016133194A1 (ja) | 2015-02-20 | 2016-08-25 | 第一三共株式会社 | がんの併用治療法 |
| BR112017019738A2 (pt) | 2015-03-20 | 2018-05-29 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| US10471154B2 (en) | 2016-08-08 | 2019-11-12 | Fei Xiao | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2020018611A1 (en) * | 2018-07-18 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators |
| KR20180093849A (ko) | 2018-08-09 | 2018-08-22 | 가톨릭대학교 산학협력단 | 줄기세포 사멸 예측 마커 및 이의 용도 |
| WO2020124043A1 (en) * | 2018-12-13 | 2020-06-18 | Gordon Erlinda M | Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy |
| KR20190060964A (ko) | 2019-05-24 | 2019-06-04 | 가톨릭대학교 산학협력단 | 줄기세포 사멸 예측 마커 및 이의 용도 |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CA3181715A1 (en) * | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| RU2766739C1 (ru) * | 2021-04-12 | 2022-03-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ прогноза эффективности терапии меланомы |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507222A (ja) * | 2003-05-28 | 2007-03-29 | ゲノミック ヘルス， インコーポレイテッド | 化学療法に対する応答を予測するための遺伝子発現マーカー |
| CN101316823B (zh) * | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| US20090311702A1 (en) * | 2008-05-12 | 2009-12-17 | Steve Shak | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CA2734363C (en) | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-07-02 AU AU2014286237A patent/AU2014286237B2/en not_active Expired - Fee Related
- 2014-07-02 WO PCT/EP2014/064039 patent/WO2015000945A1/en active Application Filing
- 2014-07-02 CA CA2912547A patent/CA2912547A1/en not_active Abandoned
- 2014-07-02 CN CN201480037933.6A patent/CN105378112B/zh not_active Expired - Fee Related
- 2014-07-02 EP EP14736727.0A patent/EP3017061B1/en not_active Not-in-force
- 2014-07-02 KR KR1020157037051A patent/KR101879926B1/ko active IP Right Grant
- 2014-07-02 BR BR112015031542A patent/BR112015031542A2/pt not_active IP Right Cessation
- 2014-07-02 JP JP2016522593A patent/JP6461126B2/ja not_active Expired - Fee Related
- 2014-07-02 RU RU2016101514A patent/RU2016101514A/ru not_active Application Discontinuation
- 2014-07-02 MX MX2015018051A patent/MX363584B/es unknown
- 2014-07-02 SG SG11201510816SA patent/SG11201510816SA/en unknown
-
2015
- 2015-11-19 IL IL242692A patent/IL242692B/en active IP Right Grant
-
2016
- 2016-03-23 HK HK16103385.9A patent/HK1215453A1/zh unknown
-
2018
- 2018-11-05 JP JP2018207947A patent/JP2019059737A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105378112A (zh) | 2016-03-02 |
| CA2912547A1 (en) | 2015-01-08 |
| KR101879926B1 (ko) | 2018-08-16 |
| MX363584B (es) | 2019-03-27 |
| WO2015000945A1 (en) | 2015-01-08 |
| EP3017061B1 (en) | 2019-01-02 |
| JP2016529880A (ja) | 2016-09-29 |
| MX2015018051A (es) | 2016-03-16 |
| HK1215453A1 (zh) | 2016-08-26 |
| EP3017061A1 (en) | 2016-05-11 |
| JP6461126B2 (ja) | 2019-01-30 |
| KR20160013214A (ko) | 2016-02-03 |
| AU2014286237A1 (en) | 2016-01-28 |
| RU2016101514A (ru) | 2017-08-08 |
| SG11201510816SA (en) | 2016-01-28 |
| RU2016101514A3 (pt) | 2018-05-28 |
| IL242692B (en) | 2019-12-31 |
| JP2019059737A (ja) | 2019-04-18 |
| AU2014286237B2 (en) | 2020-08-20 |
| CN105378112B (zh) | 2020-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015031542A2 (pt) | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| BRPI0907637A8 (pt) | biomarcadores p53 | |
| BR112012020101A2 (pt) | método diagnósticos e terapêuticos usando anticorpos anti-cd200. | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| BR112016004415A2 (pt) | método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit | |
| BR112013030606A2 (pt) | biomarcadores para terapia inibidora de hedgehog | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
| BR112013004673A8 (pt) | biomarcadores e métodos de tratamento. | |
| MX2014006404A (es) | Metodos y kits para el pronostico del cancer colorrectal. | |
| BR112012030587A2 (pt) | métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| EA201590773A1 (ru) | Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа) | |
| NZ714049A (en) | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds | |
| BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
| BR112015006284A2 (pt) | cpmf como um biomarcador para diabetes e métodos associados | |
| BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo | |
| WO2014078468A3 (en) | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent | |
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
| EA201591742A1 (ru) | Способ улучшения диагностики заболеваний с использованием измеряемых аналитов | |
| EA201401201A1 (ru) | Способ | |
| BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
| BR112017016752A2 (pt) | métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer | |
| BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2521 DE 30/04/2019. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |